Bokf Na raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.8% during the first quarter, HoldingsChannel.com reports. The fund owned 48,754 shares of the pharmaceutical company’s stock after acquiring an additional 4,737 shares during the quarter. Bokf Na’s holdings in Vertex Pharmaceuticals were worth $11,601,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Koshinski Asset Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at $307,000. Russell Investments Group Ltd. increased its position in shares of Vertex Pharmaceuticals by 87.9% during the 4th quarter. Russell Investments Group Ltd. now owns 103,543 shares of the pharmaceutical company’s stock worth $22,666,000 after purchasing an additional 48,437 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $323,000. Parallel Advisors LLC lifted its holdings in Vertex Pharmaceuticals by 4.4% during the 4th quarter. Parallel Advisors LLC now owns 1,127 shares of the pharmaceutical company’s stock valued at $247,000 after purchasing an additional 48 shares during the last quarter. Finally, GWM Advisors LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $212,000. Hedge funds and other institutional investors own 93.40% of the company’s stock.

In related news, Chairman Jeffrey M. Leiden sold 94,372 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $269.94, for a total value of $25,474,777.68. Following the completion of the sale, the chairman now owns 76,707 shares in the company, valued at approximately $20,706,287.58. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Amit Sachdev sold 13,356 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $270.01, for a total value of $3,606,253.56. Following the sale, the executive vice president now directly owns 67,603 shares in the company, valued at approximately $18,253,486.03. The disclosure for this sale can be found here. Insiders sold a total of 275,523 shares of company stock worth $75,657,835 over the last quarter. 0.48% of the stock is currently owned by corporate insiders.

VRTX has been the subject of a number of research analyst reports. Argus lifted their target price on shares of Vertex Pharmaceuticals from $270.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Cowen reiterated a “buy” rating and issued a $260.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 3rd. HC Wainwright increased their target price on Vertex Pharmaceuticals from $270.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Morgan Stanley raised their target price on Vertex Pharmaceuticals from $258.00 to $277.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, BidaskClub upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 15th. Eight analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $278.81.

Shares of Vertex Pharmaceuticals stock traded down $7.63 during trading on Wednesday, reaching $276.64. 1,137,560 shares of the company were exchanged, compared to its average volume of 1,941,448. The business has a 50-day moving average price of $272.14 and a 200-day moving average price of $238.18. The firm has a market capitalization of $74.32 billion, a price-to-earnings ratio of 47.77, a P/E/G ratio of 1.39 and a beta of 0.95. The company has a quick ratio of 3.42, a current ratio of 3.54 and a debt-to-equity ratio of 0.08. Vertex Pharmaceuticals Incorporated has a twelve month low of $165.23 and a twelve month high of $295.55.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, April 29th. The pharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.84 by $0.72. The firm had revenue of $1.52 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Vertex Pharmaceuticals had a return on equity of 25.69% and a net margin of 31.35%. The company’s revenue was up 76.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.14 earnings per share. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 7.31 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Further Reading: What is a growth and income fund?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.